Kinase inhibitors

US2016376232A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016376232-A1
Application numberUS-201615261174-A
CountryUS
Kind codeA1
Filing dateSep 9, 2016
Priority dateApr 2, 2013
Publication dateDec 29, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

There are provided compounds of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

First claim

Opening claim text (preview).

What is claimed is: 1 . A compound of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy. 2 . A compound of formula IIb, as claimed in claim 1 , wherein LG 1 represents phenoxy.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

  • Antihypertensives · CPC title

  • Immunosuppressants, e.g. drugs for graft rejection · CPC title

  • Drugs for immunological or allergic disorders · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016376232A1 cover?
There are provided compounds of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enz…
Who is the assignee on this patent?
Respivert Ltd, Topivert Pharma Ltd
What technology area does this patent fall under?
Primary CPC classification A61K31/44. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Dec 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).